Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study Comparing the Efficacy and Safety Between IBI308 and Docetaxel in Patients With Advanced or Metastatic NSCLC

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03150875
Recruitment Status : Unknown
Verified May 2017 by Innovent Biologics (Suzhou) Co. Ltd..
Recruitment status was:  Recruiting
First Posted : May 12, 2017
Last Update Posted : November 30, 2017
Sponsor:
Information provided by (Responsible Party):
Innovent Biologics (Suzhou) Co. Ltd.

Brief Summary:

Similar clinical trial results demonstrated that anti-PD-1 antibodies prolonged OS to approximately 9 months compared with 6 months in docetaxel group. Anti-PD-1 therapy in Chinese squamous NSCLC patients will be investigated in this clinical trial.

Additionally the correlation between PD-L1 expression and the response to IBI308 treatment in Chinese squamous cell NSCLC as well as the role of irRECIST in immune checkpoint inhibitor treatment evaluation will also be assessed


Condition or disease Intervention/treatment Phase
Squamous Cell Lung Carcinoma Biological: IBI308 Drug: Docetaxel Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 266 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Efficacy and Safety Evaluation of IBI308 Versus Docetaxel in Patients With Advanced or Metastatic Squamous Cell Lung Cancer After Failure of First-line Platinum-based Therapy- a Randomized, Open-label, Multicenter, Parallel, Phase 3 Study (ORIENT-3)
Actual Study Start Date : September 1, 2017
Estimated Primary Completion Date : September 2018
Estimated Study Completion Date : September 2018

Resource links provided by the National Library of Medicine

Drug Information available for: Docetaxel

Arm Intervention/treatment
Experimental: IBI308
injection; dosage form: 10ml:100mg; frequency: 200mgQ3W; duration: randomization to the date of the first documented tumor progression per RECIST v1.1 criteria
Biological: IBI308
Anti-PD-1 therapy in Chinese non-squamous NSCLC patients will be investigated in this clinical trial.

Active Comparator: docetaxel
injection; dosage form: 1ml:40mg; Frequency: 75mg/m2 Q3W; duration: randomization to the date of the first documented tumor progression per RECIST v1.1 criteria
Drug: Docetaxel
As 2nd line treatment to subjects with non-squamous NSCLC




Primary Outcome Measures :
  1. OS (overall survival) [ Time Frame: up to 24 months after randomization ]
    OS was defined as the time between the date of randomization and the date of death from any cause.


Secondary Outcome Measures :
  1. PFS (progression free survival) [ Time Frame: up to 24 months after randomization] ]
    PFS was defined as the time from the date of randomization to the date of the first documented tumor progression per RECIST v1.1 criteria

  2. ORR(objective response rate) [ Time Frame: up to 24 months after randomization ]
    Objective response is defined as best overall response (CR or PR) across all assessment time points during the period from enrolment to termination of trial treatment(per RECIST v1.1).

  3. DOR(Duration of objective response) [ Time Frame: up to 24 months after randomization ]
    DOR is defined as the time from the date of first confirmed response to the date of the first documented tumor progression (per RECIST v1.1)

  4. DCR(Disease control rate) [ Time Frame: up to 24 months after randomization ]
    DOR is defined as the time from the date of first confirmed response to the date of the first documented tumor progression (per RECIST v1.1)

  5. AEs [ Time Frame: up to 24 months after screening ]
    Number of participants with treatment-related adverse events (AEs)


Other Outcome Measures:
  1. Exploratory Outcome Measure [ Time Frame: From randomiziont up to 6 months after last subject out ]
    PD-L1 expression

  2. Exploratory Outcome Measure [ Time Frame: From randomiziont up to 6 months after last subject out ]
    Immune-related gene expression as predictors for anti-PD-L1 expression and immune-related gene expression as predictors for anti-PD-1 therapy in squamous cell NSCLC; The role of irRECIST in anti-PD-1 therapy evaluation;



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Subjects with Histologically or cytologically confirmed squamous cell NSCLC
  2. Subjects with stage IIIB/stage IV or recurrent disease (not suitable for definitive concurrent chemoradiotherapy) (according to version 7 of the International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology) after failure of first-line platinum-based therapy; Subjects who developed recurrent disease <6 months after platinum-containing adjuvant, neoadjuvant or definitive chemoradiation therapy also could also be eligible.
  3. At lease one measurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1
  4. Age ≥ 18 and ≤ 75
  5. ECOG performance status 0-1
  6. Life expectancy of at least 12 weeks
  7. Adequate organ and bone marrow function

    1. CBC: absolute neutrophil count (ANC) ≥ 1.5 × 109 / L; platelet count (PLT) ≥ 100 × 109 / L; hemoglobin content (HGB) ≥ 9.0 g / dL.
    2. Liver function: serum total bilirubin (TBIL) ≤ 1.5 × normal upper limit (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN; serum albumin ≥ 28 g / L.
    3. Renal function: serum creatinine (Cr) ≤ 1.5 × ULN, or creatinine clearance rate (Ccr) ≥ 40 mL / min (calculated using Cockcroft / Gault equation) Female:CrCl= (140-Age) x Weight(kg) x 0.85 72 x Serum creatinine (mg/dL) Male:CrCl= (140-Age) x Weight(kg) x 1.00 72 x Serum creatinine (mg/dL)
  8. Subjects of reproductive potential must be willing to use adequate contraception during the course of the study and through 6 months after the last dose of study treatment.
  9. Voluntarily signed written informed consent form, willing and able to comply with scheduled visits and other requirements of the study

Exclusion Criteria:

  1. EGFR mutation and ALK rearrangement
  2. Mixed adeno-squamous carcinoma or other pathological type
  3. Prior therapy with anti-PD-1,anti-PD-L1,anti-CTLA4 antibody or docetaxel
  4. Have received following treatment:

    1. Received any investigational agent within 4 weeks of the first dose of study treatment.
    2. Received any anti-tumor therapy (chemotherapy, targeted therapy, tumor immunotherapy or arterial embolization) within 3 weeks of the first dose of study treatment.
    3. Received radiotherapy within 4 weeks of the first dose of study treatment.
    4. Received systemic treatment with high-dose corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive drugs within 4 weeks of first dose. Inhaled or topical steroids and adrenal replacement steroid are permitted in the absence of active autoimmune disease.
    5. Received attenuated live vaccine within 4 weeks of the first dose of study medication or plan to receive live vaccine during study period.
    6. Received major surgery (such as craniotomy, thoracotomy or laparotomy) within 4 weeks of the first dose of study drugs or open wound, ulcer or fracture.
  5. Unrecovered toxicity (grade >1, according to NCI CTCAE 4.03) due to prior anti-tumor therapy before the first dose of study treatment.
  6. Subjects with active, known or suspected autoimmune disease such as interstitial pneumonia, uveitis, Crohn's disease, autoimmune thyroiditis. Subjects with cured childhood asthma, type I diabetes mellitus and hypothyroidism only requiring hormone replacement, or skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment.
  7. Known history of allogeneic organ or allogeneic hemopoietic stem cell transplantation
  8. Known allergic or hypersensitive to docetaxel, any monoclonal antibody or any other components used in their preparation.
  9. Hemoptysis within 4 weeks of randomization (≥ 1/2 spoon per time).
  10. Received thoracic radiotherapy >30Gy within 6 months or palliative radiotherapy (brain or bone metastasis) ≤30Gy within 7 days of randomization.
  11. Symptomatic central nervous system (CNS) metastasis and/or carcinomatous meningitis. Subjects should have stable disease more than 4 weeks from first dose of study treatment, with neurological symptoms returned to NCI CTCAE 4.03 grade 0 or 1, are permitted to enroll.
  12. Subjects with a history of interstitial lung disease
  13. Superior vena caval obstruction syndrome;
  14. Uncontrolled third space effusion, eg. ascites or pleural effusion.
  15. Uncontrolled concomitant disease, including but not limited to :

    1. Active or poorly controlled severe infection
    2. Human Immunodeficiency Virus (HIV) infection (HIV antibody positive)
    3. Known acute or chronic active hepatitis B (HBV DNA positive) infection or acute or chronic active hepatitis C (HCV antibody positive and HCV RNA positive) infection
    4. Active tuberculosis
    5. Symptomatic congestive heart failure (New York Heart Association grade III-IV) or symptomatic, poorly controlled arrhythmia
    6. Uncontrolled hypertension (SBP ≥ 160mmHg or DBP ≥ 100mmHg)
    7. Prior arterial thromboembolism event, including myocardial infarction, unstable angina, stroke and transient ischemic attack, within 6 months of enrollment
    8. Concomitant disease needs anticoagulant therapy
    9. Uncontrolled hypercalcemia(Ca2+>1.5mmol/L or Ca >12mg/dl or corrected Serum Calcium >ULN),or Symptomatic hypercalcemia during diphosphonate therapy
    10. Other primary malignancy, with the exception of: (radical Non-melanoma skin cancer or cured cervical in-situ carcinoma;)
  16. Subjects with other diseases or abnormal Lab test results which might increase the risk of enrollment and treatment or Interfere with the interpretation of study results could be excluded according to the judgments of investigator.
  17. Women who are pregnant or nursing

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03150875


Contacts
Layout table for location contacts
Contact: Han Fu, master +86 21-31836973 han.fu@innoventbio.com

Locations
Layout table for location information
China, Zhejiang
Zhejiang Cancer Hospital Recruiting
Hangzhou, Zhejiang, China, 310022
Contact: Xinmin Yu, MD    0571-88122167    yuxm@zjcc.org.cn   
The First Affiliated Hospital Zhejiang University Recruiting
Hangzhou, Zhejiang, China
Contact: Jianying Zhou         
Sponsors and Collaborators
Innovent Biologics (Suzhou) Co. Ltd.
Investigators
Layout table for investigator information
Principal Investigator: Yankai Shi, Doctor Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Layout table for additonal information
Responsible Party: Innovent Biologics (Suzhou) Co. Ltd.
ClinicalTrials.gov Identifier: NCT03150875     History of Changes
Other Study ID Numbers: CIBI308C301
First Posted: May 12, 2017    Key Record Dates
Last Update Posted: November 30, 2017
Last Verified: May 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Docetaxel
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action